We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Part one of our preview is here, with looks at key studies in... Read more »
[Updated, 4:28 pm ET, see below] After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break... Read more »
An Acadia Pharmaceuticals drug developed to treat hallucinations and delusions experienced by Parkinson’s disease patients is now showing signs it could also treat similar psychoses associated with Alzheimer’s disease.
San Diego-based Acadia (NASDAQ: ACAD) reported that patients treated in an... Read more »
’Tis the season for giving gifts. And increasingly, those shiny new toys and gadgets can be connected to the Internet—from TVs to watches, speakers to Barbie dolls.
That Internet connection opens up a ton of possibilities for how we can... Read more »
The 21st Century Cures Act is now law. New York wants to play in the biotech big leagues. The FDA under Trump will have license to approve drugs faster and could have a former top official back on board as commissioner.... Read more »
If you’re not much of a podcast listener and you have a sense that you’re missing out on a lot of great content, you’re absolutely right. But now is a good time to fix that, thanks to a new profusion of... Read more »
After taking the first steps toward the development of living human liver tissue “patches” for therapeutic use, San Diego-based Organovo (NASDAQ: ONVO) is laying out its pre-clinical data for the first time today. And the company says the results are... Read more »
Molecular Assemblies, a San Diego startup developing a new enzymatic method for synthesizing DNA, said today it has raised $2.3 million in a seed financing round.
The funding will be used to hire more scientists and to advance the company’s... Read more »
When Eli Lilly (NYSE: LLY) reported the day before Thanksgiving, that its Alzheimer’s treatment solanezumab failed to significantly improve the condition of people with a mild form of the disease, some observers immediately called it a final blow for... Read more »